S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
S&P 500   0.56 (+5.04%)
DOW   0.56 (+5.04%)
QQQ   269.38 (+1.35%)
AAPL   435.75 (+2.52%)
MSFT   216.54 (+5.62%)
FB   251.96 (-0.67%)
GOOGL   1,482.76 (-0.35%)
AMZN   3,111.89 (-1.67%)
NVDA   440.41 (+3.73%)
CGC   19.06 (+4.27%)
BABA   257.94 (+2.76%)
TSLA   1,485.00 (+3.79%)
MU   50.39 (+0.68%)
GE   6.11 (+0.66%)
AMD   77.67 (+0.31%)
T   29.62 (+0.14%)
F   6.69 (+1.21%)
ACB   10.42 (+2.26%)
GILD   71.73 (+3.16%)
NFLX   498.62 (+1.99%)
DIS   116.35 (-0.50%)
BAC   24.99 (+0.44%)
BA   162.27 (+2.70%)
Log in

NASDAQ:ATRSAntares Pharma Stock Price, Forecast & News

$2.81
+0.20 (+7.66 %)
(As of 08/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.63
Now: $2.81
$2.84
50-Day Range
$2.60
MA: $2.75
$2.91
52-Week Range
$1.60
Now: $2.81
$5.13
Volume1.60 million shs
Average Volume1.40 million shs
Market Capitalization$465.22 million
P/E Ratio140.57
Dividend YieldN/A
Beta1.3
Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.
Read More
Antares Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.6Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Current SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$123.86 million
Book Value$0.33 per share

Profitability

Net Income$-2,030,000.00

Miscellaneous

Employees165
Market Cap$465.22 million
Next Earnings Date8/6/2020 (Confirmed)
OptionableOptionable
$2.81
+0.20 (+7.66 %)
(As of 08/3/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

How has Antares Pharma's stock been impacted by COVID-19 (Coronavirus)?

Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATRS shares have decreased by 6.3% and is now trading at $2.81.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Antares Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Antares Pharma
.

When is Antares Pharma's next earnings date?

Antares Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020.
View our earnings forecast for Antares Pharma
.

How can I listen to Antares Pharma's earnings call?

Antares Pharma will be holding an earnings conference call on Thursday, August 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) released its quarterly earnings data on Tuesday, May, 5th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.00 by $0.01. The specialty pharmaceutical company earned $33.08 million during the quarter, compared to the consensus estimate of $30.50 million. Antares Pharma had a return on equity of 2.38% and a net margin of 0.86%.
View Antares Pharma's earnings history
.

What price target have analysts set for ATRS?

4 analysts have issued 12 month target prices for Antares Pharma's shares. Their forecasts range from $4.50 to $7.00. On average, they anticipate Antares Pharma's share price to reach $5.63 in the next twelve months. This suggests a possible upside of 100.2% from the stock's current price.
View analysts' price targets for Antares Pharma
.

Has Antares Pharma been receiving favorable news coverage?

Media stories about ATRS stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Antares Pharma earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future.
View the latest news about Antares Pharma
.

Who are some of Antares Pharma's key competitors?

What other stocks do shareholders of Antares Pharma own?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the following people:
  • Mr. Robert F. Apple, CEO, Pres & Director (Age 53)
  • Mr. Fred M. Powell, Exec. VP & CFO (Age 58)
  • Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)
  • Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)
  • Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56)

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

Who are Antares Pharma's major shareholders?

Antares Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Centric Wealth Management (2.17%), Assenagon Asset Management S.A. (0.27%), SG Americas Securities LLC (0.18%), Raymond James Financial Services Advisors Inc. (0.14%), Dupont Capital Management Corp (0.09%) and UBS Group AG (0.06%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity.
View institutional ownership trends for Antares Pharma
.

Which institutional investors are selling Antares Pharma stock?

ATRS stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG. Company insiders that have sold Antares Pharma company stock in the last year include Marvin Samson, Robert F Apple, and Thomas J Garrity.
View insider buying and selling activity for Antares Pharma
.

Which institutional investors are buying Antares Pharma stock?

ATRS stock was purchased by a variety of institutional investors in the last quarter, including Centric Wealth Management, Assenagon Asset Management S.A., SG Americas Securities LLC, Dupont Capital Management Corp, Perigon Wealth Management LLC, Kelman Lazarov Inc., Costello Asset Management INC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Antares Pharma
.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.81.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $465.22 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 165 workers across the globe.

What is Antares Pharma's official website?

The official website for Antares Pharma is www.antarespharma.com.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.